In peritoneal dissemination xenografts, Telotristat ethyl alone slightly increased median survival compared to controls, without statistical significance. In iCCA xenografts, Telotristat ethyl reduced net tumour growth compared to controls. In male mice exposed to CDCA enema, Telotristat ethyl significantly reduced gastrointestinal transit distance compared to the CDCA group. [2,3]
Survival in peritoneal dissemination xenografts
Animal study · peritoneal dissemination xenografts using NOD/SCID mice; n = 6–7 per group [2]
NOD/SCID mice bearing peritoneal dissemination xenografts received Telotristat ethyl at 100 mg/kg. Median survival was 52 days with treatment alone versus 47 days in controls; the increase was not statistically significant.
Conditions shared by the study groups
- Treatment course
- Ten days post‐tumour cell injection; 5 days per week; for 2 weeks
- Telotristat ethyl 100 mg/kg
- Model: peritoneal dissemination xenografts using NOD/SCID mice; n = 6–7 per group
- Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Telotristat ethyl
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Animal studies > Animal survival study (S20, S21, S22); RESULTS > Animal survival benefits of telotristat ethyl and cytotoxic agents (S57, S58)
median animal survival: median animal survival; comparator: phosphate‐buffered saline (control) — RESULTS > Animal survival benefits of telotristat ethyl and cytotoxic agents (S57, S58)
Telotristat ethyl 100 mg/kg · MATERIALS AND METHODS > Animal studies > Animal survival study (S22); RESULTS > Animal survival benefits of telotristat ethyl and cytotoxic agents (S57, S58)
Gastrointestinal transit after CDCA exposure
Animal study · Male C57BL/6 mice; 5 mice [3]
Male mice received Telotristat ethyl at 200 mg/kg by intraperitoneal injection after CDCA enema exposure. Compared to the CDCA group, gastrointestinal transit distance 30 minutes after carmine administration was significantly reduced in the Telotristat ethyl group.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- After 7 days of CDCA (20 mg/kg) enema; for 7 consecutive days
- Telotristat ethyl 200 mg/kg
- Model: Male C57BL/6 mice; 5 mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Telotristat ethyl; Compound label in the paper: LX1606
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > CDCA treatment in mice (S32); Methods > Carmine red assay for intestinal motility (S45); Methods > Tph1 inhibitor and 5-HTRs antagonists (S52, S53, S54, S55); Results > Inhibition of 5-HT synthesis or blocking 5-HT receptors reversed CDCA-induced enhancement of intestinal motility (S111)
GI transit distance 30 minutes after carmine administration: GI transit distance 30 minutes after carmine administration; comparator: The Control group and the CDCA (20 mg/kg) group received PBS via intraperitoneal injection. — Results > Inhibition of 5-HT synthesis or blocking 5-HT receptors reversed CDCA-induced enhancement of intestinal motility (S111)
Telotristat ethyl 200 mg/kg · Methods > Tph1 inhibitor and 5-HTRs antagonists (S52, S53); Results > Inhibition of 5-HT synthesis or blocking 5-HT receptors reversed CDCA-induced enhancement of intestinal motility (S111)
Tumour growth in iCCA xenografts
Animal study · iCCA CC‐LP‐1 xenografts; NOD/SCID mice; at least five mice per group [2]
NOD/SCID mice bearing iCCA xenografts received Telotristat ethyl at 100 mg/kg. Net tumour growth was reduced to 93 mm3 compared to 199 mm3 in controls.
Conditions shared by the study groups
- Treatment course
- Ten days after tumour cell injection; 5 days per week; for 2 weeks
- Telotristat ethyl 100 mg/kg
- Model: iCCA CC‐LP‐1 xenografts; NOD/SCID mice; at least five mice per group
- Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Telotristat ethyl
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Animal studies > Tumour growth inhibition studies in CDX models (S26, S28, S29); RESULTS > Tumour growth inhibition by telotristat ethyl and cytotoxic agents in cell‐derived xenografts (S64, S66); FIGURE 2 legend (S125, S126)
Net tumour growth: Net tumour growth; comparator: PBS (control) — RESULTS > Tumour growth inhibition by telotristat ethyl and cytotoxic agents in cell‐derived xenografts (S66)
Telotristat ethyl 100 mg/kg · MATERIALS AND METHODS > Animal studies > Tumour growth inhibition studies in CDX models (S29); RESULTS > Tumour growth inhibition by telotristat ethyl and cytotoxic agents in cell‐derived xenografts (S66); FIGURE 2 legend (S126)